Program
Tenecteplase
Also written as “tenecteplase”, “rhTNK-tPA” and “GNR-060”.
Its studies are mostly in Myocardial Infarction · Ischemic Stroke · ST Elevation Myocardial Infarction · Stroke · Heart Arrest, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 81 open or running | phase 4since Sep 9, 2005 | Sep 7, 2005 | Oct 2, 2027phase 3 · NCT07361302 |
| Hoffmann-La Roche | 50 open or running | phase 3since Nov 2, 2006 | Nov 2, 2006 | none ahead |
| CSPC Pharmaceutical Group | 21 open or running | phase 4since Jun 12, 2016 | Jun 12, 2016 | Sep 30, 2027phase 3 · NCT07201688 |
| AO GENERIUM | 10 open or running | phase 3since Oct 26, 2022 | Oct 26, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 7, 2005First studies: 2 phase 3 studiesNew to Boehringer IngelheimBoehringer Ingelheim · NCT00148460, NCT00157261
- Sep 9, 2005Phase 4 study in Myocardial InfarctionBoehringer Ingelheim · NCT00168792 · 1,671 enrolled · United States, Austria, Belgium and more
- Nov 2, 2006Hoffmann-La Roche's first studies: 4 phase 3 studiesNew to Hoffmann-La RocheHoffmann-La Roche · NCT00396318, NCT00396253, NCT00396032 and 1 more
- Feb 15, 2008Phase 3 study in Myocardial InfarctionBoehringer Ingelheim · NCT00623623 · 1,899 enrolled · Austria, Belgium, Brazil and more
- Jul 2, 20142 phase 3 studies in Myocardial InfarctionBoehringer Ingelheim · NCT02182011, NCT02181985
- Jun 12, 2016CSPC Pharmaceutical Group's first study: phase 4 study in Acute ST Elevation Myocardial InfarctionNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT02835534 · 818 enrolled · China
- Dec 19, 2018Phase 3 study in THROMBOLYSISHoffmann-La Roche · NCT03785678 · 458 enrolled · United States, Canada
- Jun 4, 2021Phase 3 study in StrokeBoehringer Ingelheim · NCT04915729 · 1,489 enrolled · China
- Oct 26, 2022AO GENERIUM's first study: phase 3 study in ST Elevation Myocardial InfarctionNew to AO GENERIUMAO GENERIUM · NCT05601999 · 244 enrolled · Russia
- Sep 22, 2025Phase 3 study in Ischemic StrokeCSPC Pharmaceutical Group · NCT07201688 · 890 planned · China
- Jan 14, 2026Phase 3 study in Ischemic StrokeBoehringer Ingelheim · NCT07361302 · 1,325 planned · Argentina, Australia, Bulgaria and more
Ahead
- Sep 30, 2027Primary completion: phase 3 study in Ischemic StrokeCSPC Pharmaceutical Group · NCT07201688
- Oct 2, 2027Primary completion: phase 3 study in Ischemic StrokeBoehringer Ingelheim · NCT07361302
TargetBeta
“Tissue-type plasminogen activator exogenous protein”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07361302Ischemic Stroke · Argentina, Australia, Bulgaria and more | 3 | Recruiting | Boehringer Ingelheim | Oct 2, 2027 | 1,325 |
| NCT07201688Ischemic Stroke · China | 3 | Recruiting | CSPC Pharmaceutical Group | Sep 30, 2027 | 890 |
| NCT05601999ST Elevation Myocardial Infarction · Russia | 3 | Completed | AO GENERIUM | May 6, 2024 | 244 |
| NCT04915729Stroke · China | 3 | Completed | Boehringer Ingelheim | Oct 8, 2023 | 1,489 |
| NCT03785678THROMBOLYSIS · United States, Canada | 3 | Completed | Hoffmann-La Roche | Feb 28, 2023 | 458 |
| NCT02835534Acute ST Elevation Myocardial Infarction · China | 4 | Completed | CSPC Pharmaceutical Group | Oct 2019 | 818 |
| NCT02182011Myocardial Infarction | 3 | Completed | Boehringer Ingelheim | Jun 2001 | 49 |
| NCT02181985Myocardial Infarction | 3 | Completed | Boehringer Ingelheim | Apr 2001 | 5,989 |
| NCT00623623Myocardial Infarction · Austria, Belgium, Brazil and more | 3 | Completed | Boehringer Ingelheim | Sep 1, 2012 | 1,899 |
| NCT00396318Dysfunctional Central Venous Access Catheters | 3 | Completed | Hoffmann-La Roche | Jun 2008 | 251 |
| NCT00396253Dysfunctional Hemodialysis Catheters | 3 | Completed | Hoffmann-La Roche | Oct 2008 | 223 |
| NCT00396032Renal Insufficiency | 3 | Completed | Hoffmann-La Roche | Dec 2008 | 150 |
| NCT00395876Dysfunctional Central Venous Access Catheters | 3 | Completed | Hoffmann-La Roche | Jun 2008 | 100 |
| NCT00168792Myocardial Infarction · United States, Austria, Belgium and more | 4 | Terminated | Boehringer Ingelheim | Jul 2006 | 1,671 |
| NCT00157261Heart Arrest · Austria, Belgium, France and more | 3 | Terminated | Boehringer Ingelheim | Jun 2006 | 1,050 |
| NCT00148460Myocardial Infarction · China, Hong Kong, Korea, Republic of | 3 | Completed | Boehringer Ingelheim | 270 |
How it is read
Names in the registry
- “tenecteplase”, 6 entries
- “Tenecteplase”, 5 entries
- “rhTNK-tPA”, 2 entries
- “GNR-060”, 1 entry
- “Full dose TNK-tPA”, 1 entry
Conditions, from the studies’ own filings
- Myocardial Infarction, 5 studies
- Ischemic Stroke, 2 studies
- ST Elevation Myocardial Infarction, 2 studies
- Stroke, 1 study
- Heart Arrest, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.